Identification of a bisphosphonate that inhibits isopentenyl diphosphate isomerase and farnesyl diphosphate synthase

Keith Thompson, James Edward Dunford, F. H. Ebetino, Michael John Rogers

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

We and others have recently shown that the major molecular target of nitrogen-containing bisphosphonate drugs is farnesyl diphosphate synthase, an enzyme in the mevalonate pathway. In an in vitro screen, we discovered a bisphosphonate, NE21650, that potently inhibited farnesyl diphosphate synthase but, unlike other N-BPs investigated, was also a weak inhibitor of isopentenyl diphosphate isomerase. NE21650 was a more potent inhibitor of protein prenylation in osteoclasts and macrophages, and a more potent inhibitor of bone resorption in vitro, than alendronate, despite very similar IC50 values for inhibition of farnesyl diphosphate synthase. Our observations show that minor changes to the structure of bisphosphonates allow inhibition of more than one enzyme in the mevalonate pathway and suggest that loss of protein prenylation due to inhibition of more than one enzyme in the mevalonate pathway may lead to an increase in antiresorptive potency compared to bisphosphonates that only inhibit farnesyl diphosphate synthase. (C) 2002 Elsevier Science.

Original languageEnglish
Pages (from-to)869-873
Number of pages5
JournalBiochemical and Biophysical Research Communications
Volume290
Issue number2
DOIs
Publication statusPublished - 18 Jan 2002

Keywords

  • bisphosphonate
  • farnesyl diphosphate synthase
  • isopentenyl diphosphate isomerase
  • mevalonate
  • prenylation
  • osteoclast
  • nitrogen-containing bisphosphonates
  • mevalonate pathway
  • osteoclast formation
  • bone-resorption
  • in-vitro
  • geranylation
  • alendronate
  • activation
  • mechanism
  • kinase

Cite this

Identification of a bisphosphonate that inhibits isopentenyl diphosphate isomerase and farnesyl diphosphate synthase. / Thompson, Keith; Dunford, James Edward; Ebetino, F. H.; Rogers, Michael John.

In: Biochemical and Biophysical Research Communications, Vol. 290, No. 2, 18.01.2002, p. 869-873.

Research output: Contribution to journalArticle

Thompson, Keith ; Dunford, James Edward ; Ebetino, F. H. ; Rogers, Michael John. / Identification of a bisphosphonate that inhibits isopentenyl diphosphate isomerase and farnesyl diphosphate synthase. In: Biochemical and Biophysical Research Communications. 2002 ; Vol. 290, No. 2. pp. 869-873.
@article{8ceb9884f7c445cd9835f0fba509cc02,
title = "Identification of a bisphosphonate that inhibits isopentenyl diphosphate isomerase and farnesyl diphosphate synthase",
abstract = "We and others have recently shown that the major molecular target of nitrogen-containing bisphosphonate drugs is farnesyl diphosphate synthase, an enzyme in the mevalonate pathway. In an in vitro screen, we discovered a bisphosphonate, NE21650, that potently inhibited farnesyl diphosphate synthase but, unlike other N-BPs investigated, was also a weak inhibitor of isopentenyl diphosphate isomerase. NE21650 was a more potent inhibitor of protein prenylation in osteoclasts and macrophages, and a more potent inhibitor of bone resorption in vitro, than alendronate, despite very similar IC50 values for inhibition of farnesyl diphosphate synthase. Our observations show that minor changes to the structure of bisphosphonates allow inhibition of more than one enzyme in the mevalonate pathway and suggest that loss of protein prenylation due to inhibition of more than one enzyme in the mevalonate pathway may lead to an increase in antiresorptive potency compared to bisphosphonates that only inhibit farnesyl diphosphate synthase. (C) 2002 Elsevier Science.",
keywords = "bisphosphonate, farnesyl diphosphate synthase, isopentenyl diphosphate isomerase, mevalonate, prenylation, osteoclast, nitrogen-containing bisphosphonates, mevalonate pathway, osteoclast formation, bone-resorption, in-vitro, geranylation, alendronate, activation, mechanism, kinase",
author = "Keith Thompson and Dunford, {James Edward} and Ebetino, {F. H.} and Rogers, {Michael John}",
year = "2002",
month = "1",
day = "18",
doi = "10.1006/bbrc.2001.6289",
language = "English",
volume = "290",
pages = "869--873",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Identification of a bisphosphonate that inhibits isopentenyl diphosphate isomerase and farnesyl diphosphate synthase

AU - Thompson, Keith

AU - Dunford, James Edward

AU - Ebetino, F. H.

AU - Rogers, Michael John

PY - 2002/1/18

Y1 - 2002/1/18

N2 - We and others have recently shown that the major molecular target of nitrogen-containing bisphosphonate drugs is farnesyl diphosphate synthase, an enzyme in the mevalonate pathway. In an in vitro screen, we discovered a bisphosphonate, NE21650, that potently inhibited farnesyl diphosphate synthase but, unlike other N-BPs investigated, was also a weak inhibitor of isopentenyl diphosphate isomerase. NE21650 was a more potent inhibitor of protein prenylation in osteoclasts and macrophages, and a more potent inhibitor of bone resorption in vitro, than alendronate, despite very similar IC50 values for inhibition of farnesyl diphosphate synthase. Our observations show that minor changes to the structure of bisphosphonates allow inhibition of more than one enzyme in the mevalonate pathway and suggest that loss of protein prenylation due to inhibition of more than one enzyme in the mevalonate pathway may lead to an increase in antiresorptive potency compared to bisphosphonates that only inhibit farnesyl diphosphate synthase. (C) 2002 Elsevier Science.

AB - We and others have recently shown that the major molecular target of nitrogen-containing bisphosphonate drugs is farnesyl diphosphate synthase, an enzyme in the mevalonate pathway. In an in vitro screen, we discovered a bisphosphonate, NE21650, that potently inhibited farnesyl diphosphate synthase but, unlike other N-BPs investigated, was also a weak inhibitor of isopentenyl diphosphate isomerase. NE21650 was a more potent inhibitor of protein prenylation in osteoclasts and macrophages, and a more potent inhibitor of bone resorption in vitro, than alendronate, despite very similar IC50 values for inhibition of farnesyl diphosphate synthase. Our observations show that minor changes to the structure of bisphosphonates allow inhibition of more than one enzyme in the mevalonate pathway and suggest that loss of protein prenylation due to inhibition of more than one enzyme in the mevalonate pathway may lead to an increase in antiresorptive potency compared to bisphosphonates that only inhibit farnesyl diphosphate synthase. (C) 2002 Elsevier Science.

KW - bisphosphonate

KW - farnesyl diphosphate synthase

KW - isopentenyl diphosphate isomerase

KW - mevalonate

KW - prenylation

KW - osteoclast

KW - nitrogen-containing bisphosphonates

KW - mevalonate pathway

KW - osteoclast formation

KW - bone-resorption

KW - in-vitro

KW - geranylation

KW - alendronate

KW - activation

KW - mechanism

KW - kinase

U2 - 10.1006/bbrc.2001.6289

DO - 10.1006/bbrc.2001.6289

M3 - Article

VL - 290

SP - 869

EP - 873

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 2

ER -